Bimekizumab Effective for AxSpA Regardless of Prior TNFi Use

Data after 24 weeks of treatment with bimekizumab in patients with axial spondyloarthritis show good responses overall regardless of prior experience with a tumor necrosis factor inhibitor.

Related Keywords

Berlin , Germany , Belgium , Xenofon Baraliakos , Eli Lilly , Bristol Myers Squibb , Amgen , Novartis , European Alliance Of Associations , Pfizer , Assessment In Spondyloarthritis International Society , European Union , Ruhr University Bochum Germany , International Congress On Spondyloarthritides , International Congress , Ruhr University Bochum , European Alliance , Spondyloarthritis International Society , Fabian Proft , Medical University , None Drug , Ankylosing Spondylitis Disease Activity Score , Bath Ankylosing Spondylitis Functional Index , Response Seen Regardless , Merck Sharp , Pain Management , Ankylosing Spondylitis Bechterews Disease , Spain , Psoriasis , Ankylosing Spondylitis , Activism , Activist , Biologic Therapy , Interleukins , Social Issues , Europe , European , Fungal Infection , Internship , Interns , Plaque Psoriasis ,